โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Etichetta canale medico: 16 negli ultimi 7 giorni ๐ŸŽ Canale alimentare: 193 negli ultimi 7 giorni ๐Ÿงธ Canale: prodotti: 48 negli ultimi 7 giorni ๐ŸŸข Monitoraggio: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Ultimo recupero: 1 ora fa โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Etichetta canale medico: 16 negli ultimi 7 giorni ๐ŸŽ Canale alimentare: 193 negli ultimi 7 giorni ๐Ÿงธ Canale: prodotti: 48 negli ultimi 7 giorni ๐ŸŸข Monitoraggio: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Ultimo recupero: 1 ora fa
๐Ÿ›ก๏ธ EUSW
๐Ÿ‡ฎ๐Ÿ‡น
๐Ÿ’Š

Eliquis

apixaban
Artroplastica; Tromboembolia venosa
โœ… Autorizzato
โœ…
Nessun allarme attivo
Questo medicinale non presenta carenze in corso, lettere di sicurezza o richiami.

A cosa serve

Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. AdultsPrevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age โ‰ฅ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class โ‰ฅ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).Paediatric population Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); ageโ‰ฅ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class โ‰ฅ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. 

โš ๏ธ Sicurezza del paziente

No

โš ๏ธ Aggregiamo avvisi ufficiali. Non forniamo consulenze mediche. Per decisioni mediche o legali, consulta l'ente di riferimento e un professionista qualificato.